Marshall Wace

Marshall Wace is an investment firm with over $22 billion in assets under management.

Business Model:

Revenue: $25M

Employees: 201-500

Rankings

Detailed Marshall Wace Information

Geographic Data

Marshall Wace headquarters map

Address: George House, 131 Sloane Street

City: London

State: england

Zip: SW1X 9AT

Country: GB

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$21M

Metrics

1,900,932Website Global Rank

11,444Website Monthly Traffic

Twitter Followers

Description

Founded in 1997, Marshall Wace is a hedge fund manager specializing in global long/short equity. The firm has investment management offices in London; New York; and Hong Kong. Marshall Wace LLP was named Management Firm of the Year by the EuroHedge Awards 2011, reflecting the strong performance delivered by a number of our funds during the year. The firm is dedicated to the objective of providing its clients with a persistent, risk-adjusted return on their investment. Through a range of products, investors can select funds offering variable sources of alpha and beta, in different combinations, from equity markets around the world. Marshall Wace brings together two distinct but complementary approaches to asset management. First, traditional, fundamental long/short investing grounded in stock-specific analytical research, and secondly, Marshall Wace TOPS (‘MW TOPS’), the pioneering, and proprietary, systematic, alpha capture strategy.

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
11/2021 Acrivon Therapeutics Series B 0
11/2022 TRM Labs Series B 0
4/2021 Exscientia Series D 225M
7/2021 Amylyx Pharmaceuticals Series C 0
9/2021 INBRACE Series D 0
11/2021 Vayana Network Series C 0
1/2022 Metagenomi Series B 0
10/2022 VectivBio Post-IPO Equity 0
9/2021 Varo Money Series E 0
5/2021 Circle Venture Round 0
9/2022 Neurolens Venture Round 67.6M
6/2022 Elektrofi Series B 0
2/2022 Parse Biosciences Series B 0
1/2022 Accelerant Private Equity Round 0
11/2021 ConsenSys Series C 0
12/2021 TRM Labs Series B 0
10/2020 International Airlines Group (IAG) Post-IPO Equity 182.2M
1/2022 Lukka Series E 0
9/2020 LGI Homes Post-IPO Equity 1.5M
4/2021 Forge Biologics Series B 120M
12/2021 Tipalti Series F 0
8/2021 Neurogastrx Series B 60M
2/2022 ConsenSys Series D 0
5/2021 Pine Labs Venture Round 0
4/2022 Circle Private Equity Round 0
12/2022 Karyopharm Therapeutics Post-IPO Equity 0
9/2022 21.co Equity 25M
4/2022 Turtlemint Series E 0
9/2021 Asher Bio Series B 0
3/2021 Flywire Series F 60M
3/2021 Century Therapeutics Series C 0
10/2021 CRED Series E 251M
9/2022 ACELYRIN Series C 0
11/2021 ACELYRIN Series B 0
6/2022 Elektrofi Series B 0
4/2022 Turtlemint Series E 0
4/2022 Circle Private Equity Round 0
2/2022 Parse Biosciences Series B 0
2/2022 ConsenSys Series D 0
1/2022 Metagenomi Series B 0
1/2022 Lukka Series E 0
1/2022 Accelerant Private Equity Round 0
12/2021 Tipalti Series F 0
12/2021 TRM Labs Series B 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research